MARKET

PRVL

PRVL

Prevail
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.19
+0.48
+4.10%
Closed 16:00 03/31 EDT
OPEN
11.70
PREV CLOSE
11.71
HIGH
12.48
LOW
11.62
VOLUME
137.11K
TURNOVER
--
52 WEEK HIGH
19.25
52 WEEK LOW
7.41
MARKET CAP
416.54M
P/E (TTM)
-4.2640
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PRVL stock price target is 21.60 with a high estimate of 25.00 and a low estimate of 19.00.

EPS

PRVL News

More
  • Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimers and Parkinsons Therapies
  • GlobeNewswire · 21h ago
  • Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
  • GlobeNewswire · 5d ago
  • Prevail Therapeutics' PR006 Fast Track'd to slow the progression of FTD-GRN
  • seekingalpha · 03/24 16:41
  • Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation
  • GlobeNewswire · 03/24 12:00

Industry

Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Symbol
Price
%Change

About PRVL

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.
More

Webull offers kinds of Prevail Therapeutics Inc stock information, including NASDAQ:PRVL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRVL stock news, and many more online research tools to help you make informed decisions.